The global blood preparation market size was estimated at USD 53.56 billion in 2025 and is anticipated to reach USD 91.88 billion by 2033, growing at a CAGR of 7.1% from 2026 to 2033. The growing incidence of blood-related disorders, the rising number of transfusion procedures, and the increasing number of donations are the major factors driving the market.
Moreover, extensive usage of blood and its components in several surgical procedures, increasing number of accidents, and growing donations are also expected to fuel the market growth over the study period. For instance, according to the American National Red Cross, in the U.S., approximately 6.8 million people donate blood, and about 13.6 million units of red blood cells and whole blood are collected annually in the U.S.
The increasing prevalence of blood-related disorders, such as anemia, hemophilia, leukemia, and thrombocytopenia, is a primary driver for the growth of the global blood preparation market. According to the World Health Organization (WHO), it is estimated that anemia affects nearly 1.6 billion people globally, increasing the demand for red blood cell concentrates and iron supplements. Similarly, hemophilia affects approximately 400,000 people worldwide, requiring regular access to plasma-derived products such as clotting factors. In addition, according to a report published by the Institute for Health Metrics and Evaluation (IHME), globally in 2021, 31.2% of women had anemia compared with 17,5% of men, keeping anemia prevalence in women rising over the years. Similarly, abnormal Complete Blood Count (CBC) test results often indicate underlying infections, thereby creating a consistent demand for diagnosis among patient.
On 4 December 2025, Parse Biosciences announced the launch of Evercode Whole Blood Fixation, a solution designed to stabilize whole blood samples immediately after collection for single-cell RNA sequencing applications. The product enables simplified sample handling by eliminating the need for immediate peripheral blood mononuclear cell (PBMC) isolation and specialized processing at collection sites. This development strengthens innovation within the blood sample preparation segment, particularly for genomics research and translational diagnostics, by enabling decentralized and more flexible blood collection workflows.
Transfusions are essential in the treatment of numerous conditions such as anemia, trauma, surgical procedures, and cancer treatments. For instance, in leukemia patients the body’s factory that makes blood damaged, hence transfusion is essential to manage the disease and its symptoms. Moreover, the rising prevalence of chronic diseases and advancements in healthcare technologies have further contributed to the growing demand for products.
In addition, increasing research and development activities on preparation methods is anticipated to propel the market growth during the review period. For instance, in December 2025, authorities in Jamshedpur ordered MGM Medical College’s blood bank to implement ELISA kits for blood screening following the submission of a probe report. The directive reinforces the importance of standardized infectious disease screening protocols in blood banks to ensure transfusion safety. Although not a commercial product launch, the incident highlights the strong regulatory oversight influencing the blood preparation and screening market, driving demand for validated blood testing kits and compliance-focused laboratory practices. Furthermore, launch of new blood bank centers across the globe are likely to offer ample opportunities for the market. For instance, in March 2023, Kenya's Ministry of Health, introduced a satellite blood bank center for improving access to quality and safe transfusion services in the region.
Furthermore, innovations in blood collection and storage technology, including apheresis, have enhanced the ability to efficiently collect specific blood components such as plasma and platelets. This supports the supply chain for advanced preparations such as plasma-derived therapies. In addition, introduction of novel technologies along with the increasing usage of plasma in the pharmaceutical industry is further projected to contribute to market growth over the forecast period. For instance, in April 2021, EryPharm introduced a medical device to manufacture cultured red blood cells in large quantities and create new blood sources for transfusions. Various governments across the globe are focusing on increasing the number of donations by applying reimbursement policies, such as monetary incentives for donors. For instance, in September 2021, The American Red Cross introduced a national initiative to reach a maximum number of donors to improve health outcomes in patients with sickle cell disease. This factor is also expected to augment the growth of the global market over the next few years.
This product will be delivered within 1-3 business days.
Moreover, extensive usage of blood and its components in several surgical procedures, increasing number of accidents, and growing donations are also expected to fuel the market growth over the study period. For instance, according to the American National Red Cross, in the U.S., approximately 6.8 million people donate blood, and about 13.6 million units of red blood cells and whole blood are collected annually in the U.S.
The increasing prevalence of blood-related disorders, such as anemia, hemophilia, leukemia, and thrombocytopenia, is a primary driver for the growth of the global blood preparation market. According to the World Health Organization (WHO), it is estimated that anemia affects nearly 1.6 billion people globally, increasing the demand for red blood cell concentrates and iron supplements. Similarly, hemophilia affects approximately 400,000 people worldwide, requiring regular access to plasma-derived products such as clotting factors. In addition, according to a report published by the Institute for Health Metrics and Evaluation (IHME), globally in 2021, 31.2% of women had anemia compared with 17,5% of men, keeping anemia prevalence in women rising over the years. Similarly, abnormal Complete Blood Count (CBC) test results often indicate underlying infections, thereby creating a consistent demand for diagnosis among patient.
On 4 December 2025, Parse Biosciences announced the launch of Evercode Whole Blood Fixation, a solution designed to stabilize whole blood samples immediately after collection for single-cell RNA sequencing applications. The product enables simplified sample handling by eliminating the need for immediate peripheral blood mononuclear cell (PBMC) isolation and specialized processing at collection sites. This development strengthens innovation within the blood sample preparation segment, particularly for genomics research and translational diagnostics, by enabling decentralized and more flexible blood collection workflows.
Transfusions are essential in the treatment of numerous conditions such as anemia, trauma, surgical procedures, and cancer treatments. For instance, in leukemia patients the body’s factory that makes blood damaged, hence transfusion is essential to manage the disease and its symptoms. Moreover, the rising prevalence of chronic diseases and advancements in healthcare technologies have further contributed to the growing demand for products.
In addition, increasing research and development activities on preparation methods is anticipated to propel the market growth during the review period. For instance, in December 2025, authorities in Jamshedpur ordered MGM Medical College’s blood bank to implement ELISA kits for blood screening following the submission of a probe report. The directive reinforces the importance of standardized infectious disease screening protocols in blood banks to ensure transfusion safety. Although not a commercial product launch, the incident highlights the strong regulatory oversight influencing the blood preparation and screening market, driving demand for validated blood testing kits and compliance-focused laboratory practices. Furthermore, launch of new blood bank centers across the globe are likely to offer ample opportunities for the market. For instance, in March 2023, Kenya's Ministry of Health, introduced a satellite blood bank center for improving access to quality and safe transfusion services in the region.
Furthermore, innovations in blood collection and storage technology, including apheresis, have enhanced the ability to efficiently collect specific blood components such as plasma and platelets. This supports the supply chain for advanced preparations such as plasma-derived therapies. In addition, introduction of novel technologies along with the increasing usage of plasma in the pharmaceutical industry is further projected to contribute to market growth over the forecast period. For instance, in April 2021, EryPharm introduced a medical device to manufacture cultured red blood cells in large quantities and create new blood sources for transfusions. Various governments across the globe are focusing on increasing the number of donations by applying reimbursement policies, such as monetary incentives for donors. For instance, in September 2021, The American Red Cross introduced a national initiative to reach a maximum number of donors to improve health outcomes in patients with sickle cell disease. This factor is also expected to augment the growth of the global market over the next few years.
Global Blood Preparation Market Report Segmentation
This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global blood preparation market report based on product, antithrombotic & anticoagulants, application, and region:Product Outlook (Revenue, USD Million, 2021-2033)
- Whole Blood
- Red Cells
- Granulocytes
- Plasma
- Platelets
- Blood Components
- Whole Blood Components
- Packed Red Cells
- Leukocyte Reduced Red Blood Cells
- Frozen Plasma
- Platelet Concentrate
- Cryoprecipitate
- Blood Derivatives
Antithrombotic and Anticoagulants Outlook (Revenue, USD Million, 2021-2033)
- Platelet Aggregation Inhibitors
- Glycoprotein Inhibitors
- COX Inhibitors
- ADP Antagonists
- Others
- Fibrinolytics
- Tissue Plasminogen Activator (tPA)
- Streptokinase
- Urokinase
- Anticoagulants
- Heparins
- Unfractionated Heparin
- Low Molecular Weight Heparin (LMWH)
- Ultra-low Molecular Weight Heparin
- Vitamin K Antagonists
- Direct Thrombin Inhibitors
- Direct Factor Xa Inhibitors
Application Outlook (Revenue, USD Million, 2021-2033)
- Thrombocytosis
- Pulmonary Embolism
- Renal Impairment
- Angina Blood Vessel Complications
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Blood Preparation Market Variables, Trends & Scope
Chapter 4. Blood Preparation Market: Sample Estimates & Trend Analysis
Chapter 5. Blood Preparation Market: Anti-Thrombotic and Anticoagulants Estimates & Trend Analysis
Chapter 6. Blood Preparation Market: Application Estimates & Trend Analysis
Chapter 7. Blood Preparation Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Pfizer, Inc
- Bristol-Myers Squibb Company
- Leo Pharma A/S
- Sanofi
- Xiamen Hisunny Chemical Co., LTD
- AstraZeneca plc
- Baxter International Inc
- Portola Pharmaceuticals, Inc.
- GlaxoSmithKline PLC
- Shandong East Chemical Industry Co.
- Celgene Corp
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | March 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 53.56 Billion |
| Forecasted Market Value ( USD | $ 91.88 Billion |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
